Jennison Associates LLC Intellia Therapeutics, Inc. Transaction History

Jennison Associates LLC

$155 Billion
Q2 2024

A detailed history of Jennison Associates LLC transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Jennison Associates LLC holds 39,402 shares of NTLA stock, worth $830,988. This represents 0.0% of its overall portfolio holdings.

Number of Shares

39,402

Previous 33,616 17.21%

Holding current value

$830,988

Previous $924,000 4.65%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 05, 2024	BUY	$20.02 - $27.22 $115,835 - $157,494	5,786 Added 17.21%	39,402 $881,000
Q1 2024 May 02, 2024	BUY	$23.82 - $32.8 $232,673 - $320,390	9,768 Added 40.96%	33,616 $924,000
Q4 2023 Feb 01, 2024	BUY	$23.16 - $32.34 $114,618 - $160,050	4,949 Added 26.19%	23,848 $727,000
Q3 2023 Oct 31, 2023	BUY	$31.62 - $45.78 $27,541 - $39,874	871 Added 4.83%	18,899 $597,000
Q2 2023 Aug 03, 2023	BUY	$34.58 - $46.03 $623,408 - $829,828	18,028 New	18,028 $735,000
Q2 2022 Aug 02, 2022	SELL	$38.49 - $76.21 $11.9 Million - $23.6 Million	-310,036 Closed	0 $0
Q1 2022 May 11, 2022	SELL	$58.27 - $118.99 $42.3 Million - $86.3 Million	-725,362 Reduced 70.06%	310,036 $22.5 Million
Q4 2021 Feb 08, 2022	BUY	$100.76 - $138.36 $11.8 Million - $16.2 Million	116,821 Added 12.72%	1,035,398 $122 Million
Q3 2021 Nov 09, 2021	SELL	$132.37 - $176.78 $19.7 Million - $26.3 Million	-148,920 Reduced 13.95%	918,577 $123 Million
Q2 2021 Aug 12, 2021	SELL	$60.88 - $161.91 $4.41 Million - $11.7 Million	-72,374 Reduced 6.35%	1,067,497 $173 Million
Q1 2021 May 11, 2021	BUY	$46.59 - $83.68 $46 Million - $82.7 Million	987,773 Added 649.43%	1,139,871 $91.5 Million
Q4 2020 Feb 05, 2021	BUY	$18.83 - $63.53 $2.86 Million - $9.66 Million	152,098 New	152,098 $8.27 Million

Others Institutions Holding NTLA

# of Institutions

319

Shares Held

88.4M

Call Options Held

673K

Put Options Held

865K

View Full List

About Intellia Therapeutics, Inc.

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $1.6B
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

More about NTLA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jennison Associates LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jennison Associates LLC with notifications on news.

Account

Jennison Associates LLC Intellia Therapeutics, Inc. Transaction History